Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer

Implication for 5-fluorouracil-based chemotherapy

Zhihong Lu, Ruiwen Zhang, John T. Carpenter, Robert B Diasio

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Dihydropyrimidine dehydrogenase (DPD) is the initial, rate-limiting enzyme in the catabolism of 5-fluorouracil (5-FU), one of the most widely used chemotherapeutic agents in the treatment of breast cancer. The objective of this study was to determine the population characteristics of DPD activity in patients with breast cancer as well as the frequency of DPD deficiency in this population. DPD activity in peripheral blood mononuclear cells (PBM- DPD) was determined in 360 patients with breast cancer, with the mean PBM- DPD (0.26 ± 0.01 nmol/min/mg protein) being significantly lower than that observed in female controls (0.44 ± 0.02 nmol/min/mg protein; P < 0.01). ANOVA analysis examining the significance of differences in DPD activity among various groups indicated that only disease difference (breast cancer versus normal subjects) was significant after adjustments for race and age. In the present study, 21 (5.8%) patients were considered to he DPD deficient, indicating that this pharmacogenetic syndrome may be more common than anticipated (no DPD-deficient individual was found in the controls). Significantly lower DPD activity in patients with breast cancer may predispose to 5-FU-associated toxicity. These results provide further rationale for individualizing the 5-FU dose, thus reducing the risk of toxicity and/or improving therapeutic efficacy in patients with breast cancer.

Original languageEnglish (US)
Pages (from-to)325-329
Number of pages5
JournalClinical Cancer Research
Volume4
Issue number2
StatePublished - Feb 1998
Externally publishedYes

Fingerprint

Dihydrouracil Dehydrogenase (NADP)
Fluorouracil
Breast Neoplasms
Drug Therapy
Population
Dihydropyrimidine Dehydrogenase Deficiency
Pharmacogenetics
Population Characteristics
Blood Cells
Analysis of Variance
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer : Implication for 5-fluorouracil-based chemotherapy. / Lu, Zhihong; Zhang, Ruiwen; Carpenter, John T.; Diasio, Robert B.

In: Clinical Cancer Research, Vol. 4, No. 2, 02.1998, p. 325-329.

Research output: Contribution to journalArticle

@article{48adf57008ff428a9063ae1756fa266f,
title = "Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: Implication for 5-fluorouracil-based chemotherapy",
abstract = "Dihydropyrimidine dehydrogenase (DPD) is the initial, rate-limiting enzyme in the catabolism of 5-fluorouracil (5-FU), one of the most widely used chemotherapeutic agents in the treatment of breast cancer. The objective of this study was to determine the population characteristics of DPD activity in patients with breast cancer as well as the frequency of DPD deficiency in this population. DPD activity in peripheral blood mononuclear cells (PBM- DPD) was determined in 360 patients with breast cancer, with the mean PBM- DPD (0.26 ± 0.01 nmol/min/mg protein) being significantly lower than that observed in female controls (0.44 ± 0.02 nmol/min/mg protein; P < 0.01). ANOVA analysis examining the significance of differences in DPD activity among various groups indicated that only disease difference (breast cancer versus normal subjects) was significant after adjustments for race and age. In the present study, 21 (5.8{\%}) patients were considered to he DPD deficient, indicating that this pharmacogenetic syndrome may be more common than anticipated (no DPD-deficient individual was found in the controls). Significantly lower DPD activity in patients with breast cancer may predispose to 5-FU-associated toxicity. These results provide further rationale for individualizing the 5-FU dose, thus reducing the risk of toxicity and/or improving therapeutic efficacy in patients with breast cancer.",
author = "Zhihong Lu and Ruiwen Zhang and Carpenter, {John T.} and Diasio, {Robert B}",
year = "1998",
month = "2",
language = "English (US)",
volume = "4",
pages = "325--329",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer

T2 - Implication for 5-fluorouracil-based chemotherapy

AU - Lu, Zhihong

AU - Zhang, Ruiwen

AU - Carpenter, John T.

AU - Diasio, Robert B

PY - 1998/2

Y1 - 1998/2

N2 - Dihydropyrimidine dehydrogenase (DPD) is the initial, rate-limiting enzyme in the catabolism of 5-fluorouracil (5-FU), one of the most widely used chemotherapeutic agents in the treatment of breast cancer. The objective of this study was to determine the population characteristics of DPD activity in patients with breast cancer as well as the frequency of DPD deficiency in this population. DPD activity in peripheral blood mononuclear cells (PBM- DPD) was determined in 360 patients with breast cancer, with the mean PBM- DPD (0.26 ± 0.01 nmol/min/mg protein) being significantly lower than that observed in female controls (0.44 ± 0.02 nmol/min/mg protein; P < 0.01). ANOVA analysis examining the significance of differences in DPD activity among various groups indicated that only disease difference (breast cancer versus normal subjects) was significant after adjustments for race and age. In the present study, 21 (5.8%) patients were considered to he DPD deficient, indicating that this pharmacogenetic syndrome may be more common than anticipated (no DPD-deficient individual was found in the controls). Significantly lower DPD activity in patients with breast cancer may predispose to 5-FU-associated toxicity. These results provide further rationale for individualizing the 5-FU dose, thus reducing the risk of toxicity and/or improving therapeutic efficacy in patients with breast cancer.

AB - Dihydropyrimidine dehydrogenase (DPD) is the initial, rate-limiting enzyme in the catabolism of 5-fluorouracil (5-FU), one of the most widely used chemotherapeutic agents in the treatment of breast cancer. The objective of this study was to determine the population characteristics of DPD activity in patients with breast cancer as well as the frequency of DPD deficiency in this population. DPD activity in peripheral blood mononuclear cells (PBM- DPD) was determined in 360 patients with breast cancer, with the mean PBM- DPD (0.26 ± 0.01 nmol/min/mg protein) being significantly lower than that observed in female controls (0.44 ± 0.02 nmol/min/mg protein; P < 0.01). ANOVA analysis examining the significance of differences in DPD activity among various groups indicated that only disease difference (breast cancer versus normal subjects) was significant after adjustments for race and age. In the present study, 21 (5.8%) patients were considered to he DPD deficient, indicating that this pharmacogenetic syndrome may be more common than anticipated (no DPD-deficient individual was found in the controls). Significantly lower DPD activity in patients with breast cancer may predispose to 5-FU-associated toxicity. These results provide further rationale for individualizing the 5-FU dose, thus reducing the risk of toxicity and/or improving therapeutic efficacy in patients with breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0031912432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031912432&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 325

EP - 329

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -